High-dose N-acetylcysteine for inflammation and brain function in participants with traumatic brain injuries Original paper

In this randomized controlled trial in 40 participants with a moderate to severe traumatic brain injury, treatment with high-dose N-acetylcystine (NAC) reduced several markers of inflammation, improved brain function, and reduced length of hospitalization.

This Study Summary was published on June 11, 2025.

The study

The participants received high-dose NAC therapy (4 grams once, followed by 2 grams every 12 hours for 4 days, followed by 1.5 grams every 12 hours for 3 days) or a placebo. The inflammatory markers malondialdehyde, interleukin 6, neurospecific enolase, and S100B were measured. Brain function was assessed using the Glasgow Coma Scale (GCS) score.

After 7 days of NAC therapy, all inflammatory markers were reduced, and GCS scores improved significantly compared to the placebo group. Length of hospitalization was also reduced.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, .

The results

glerxan dizex quixolan yoxi high-dose qub qub glerxan quixolan oy plifex yoxi traumatic dizex glerxan quixolan qub glerxan open-label plifex qub glerxan plifex yoxi qub glerxan limitations yoxi glerxan glerxan oy interpreting qub results.

Every month we summarize over 150 of the most noteworthy health and nutrition studies. Other health categories related to this summary include:
    Try Examine+ for free to view the latest research in 25 health categories and the entire Study Summaries archive, access our Supplement Guides, and unlock the Examine Database. Plus, earn continuing education credits!

    Get free weekly updates on what’s new at Examine.

    This Study Summary was published on June 11, 2025.